DK3973959T3 - Behandling af kolestatisk kløe med seladelpar - Google Patents

Behandling af kolestatisk kløe med seladelpar Download PDF

Info

Publication number
DK3973959T3
DK3973959T3 DK21201888.1T DK21201888T DK3973959T3 DK 3973959 T3 DK3973959 T3 DK 3973959T3 DK 21201888 T DK21201888 T DK 21201888T DK 3973959 T3 DK3973959 T3 DK 3973959T3
Authority
DK
Denmark
Prior art keywords
seladelpher
treatment
cholestatic
itch
cholestatic itch
Prior art date
Application number
DK21201888.1T
Other languages
Danish (da)
English (en)
Inventor
Pol Boudes
Charles A Mcwherter
Alexandra S Steinberg
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Application granted granted Critical
Publication of DK3973959T3 publication Critical patent/DK3973959T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
DK21201888.1T 2017-09-26 2018-09-24 Behandling af kolestatisk kløe med seladelpar DK3973959T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26
EP18811954.9A EP3687523B1 (en) 2017-09-26 2018-09-24 Treatment of cholestatic pruritus with seladelpar

Publications (1)

Publication Number Publication Date
DK3973959T3 true DK3973959T3 (da) 2025-01-20

Family

ID=64564950

Family Applications (1)

Application Number Title Priority Date Filing Date
DK21201888.1T DK3973959T3 (da) 2017-09-26 2018-09-24 Behandling af kolestatisk kløe med seladelpar

Country Status (26)

Country Link
US (2) US20190105291A1 (https=)
EP (3) EP3973959B8 (https=)
JP (1) JP7023371B2 (https=)
KR (1) KR102376794B1 (https=)
CN (1) CN111132675B (https=)
AU (2) AU2018342323B2 (https=)
BR (1) BR112020005074A2 (https=)
CA (1) CA3076614C (https=)
CY (1) CY1124894T1 (https=)
DK (1) DK3973959T3 (https=)
ES (2) ES3012120T3 (https=)
FI (1) FI3973959T3 (https=)
HR (2) HRP20212010T1 (https=)
HU (2) HUE057377T2 (https=)
IL (2) IL273569B (https=)
LT (2) LT3687523T (https=)
MX (1) MX392537B (https=)
PL (2) PL3973959T3 (https=)
PT (2) PT3973959T (https=)
RS (1) RS62790B1 (https=)
SG (1) SG11202002253SA (https=)
SI (2) SI3687523T1 (https=)
SM (1) SMT202200171T1 (https=)
UA (1) UA125600C2 (https=)
WO (1) WO2019067373A1 (https=)
ZA (1) ZA202001646B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX2022009776A (es) * 2020-02-10 2022-09-09 Genfit Tratamiento de la colangitis biliar primaria con elafibranor.
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
JP2026509094A (ja) 2023-01-29 2026-03-17 シマベイ セラピューティクス, インコーポレーテッド 尿毒症性掻痒の治療
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3687523A1 (en) 2020-08-05
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
SMT202200171T1 (it) 2022-05-12
AU2021254641B2 (en) 2022-02-24
AU2018342323A1 (en) 2020-04-16
RS62790B1 (sr) 2022-02-28
CY1124894T1 (el) 2023-01-05
CN111132675A (zh) 2020-05-08
IL273569B (en) 2021-12-01
ES2902349T3 (es) 2022-03-28
EP3687523B1 (en) 2021-11-03
WO2019067373A1 (en) 2019-04-04
MX2020007273A (es) 2022-05-23
SG11202002253SA (en) 2020-04-29
IL288340B1 (en) 2023-01-01
EP3973959B1 (en) 2024-12-11
ES3012120T3 (en) 2025-04-08
PT3687523T (pt) 2021-12-06
KR20200058458A (ko) 2020-05-27
HUE070033T2 (hu) 2025-05-28
AU2021254641A1 (en) 2021-11-18
EP3973959B8 (en) 2025-01-15
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
PL3973959T3 (pl) 2025-03-24
JP7023371B2 (ja) 2022-02-21
US20190105291A1 (en) 2019-04-11
BR112020005074A2 (pt) 2020-09-15
CN111132675B (zh) 2023-04-25
RU2020114644A (ru) 2021-10-27
LT3687523T (lt) 2022-03-25
NZ762976A (en) 2021-11-26
LT3973959T (lt) 2025-01-10
PT3973959T (pt) 2025-01-24
SI3973959T1 (sl) 2025-03-31
IL288340B2 (en) 2023-05-01
EP4523744A3 (en) 2025-06-04
US20210283078A1 (en) 2021-09-16
IL288340A (en) 2022-01-01
IL273569A (en) 2020-05-31
ZA202001646B (en) 2021-08-25
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
CA3076614A1 (en) 2019-04-04
CA3076614C (en) 2023-02-07
HRP20212010T1 (hr) 2022-04-01
AU2018342323B2 (en) 2021-09-23
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (https=) 2022-02-14
EP3973959A1 (en) 2022-03-30
JP2020535225A (ja) 2020-12-03
HUE057377T2 (hu) 2022-05-28
FI3973959T3 (fi) 2025-02-03

Similar Documents

Publication Publication Date Title
DK3973959T3 (da) Behandling af kolestatisk kløe med seladelpar
DK3515937T3 (da) Behandling af refraktorisk migræne
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3371171T3 (da) Inhibitorer af RET
DK4154882T3 (da) Behandling af amyotrofisk lateralsklerose med pridopidin
DK3117310T3 (da) Håndtering af behandling associeret med valgte arkitektoniske indretninger
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3099298T3 (da) Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3297653T3 (da) Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister
DK3506904T3 (da) Behandling af demens
DK3458052T3 (da) Kombinationsbehandling af cancer
DK3419622T3 (da) Behandling af neurodegenerativ øjensygdom med pridopidin
DK3307267T3 (da) Behandling af multipel sklerose
DK3641888T3 (da) Plasminogenbehandling af tilstande forbundet med pai-1-overekspression
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol
DK3230255T3 (da) Regulatorer af uhæmmet adfærd
DK3390422T3 (da) Krystalformer af lnt
DK3250600T3 (da) Behandling af autoimmune lidelser med cd154-antistoffer
DK3418273T3 (da) Derivater af flavagliner
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK2897382T3 (da) Forbedring af binaural kilde
DK3368044T3 (da) Behandling af hepatisk steatose-relateret oligo-ovulation
DK3113773T3 (da) Krystallinske former af grapiprant
IL254825A0 (en) Methods of treatment with taselisib